cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2012-6-78-80cardiovascular-2032Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMАртериальная гипертензия и ишемическая болезнь сердца: место антагонистов рецепторов ангиотензина IIArterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonistsТаратухинЕ. О.TaratukhinE. O.cardio03@list.ruРоссийский национальный исследовательский медицинский университет им. Н. И. Пирогова, МоскваN. I. Pirogov Russian National Medical University, Moscow2012201220121167880Copyright © Таратухин Е.О., 20122012Таратухин Е.О.Taratukhin E.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2032

В статье рассматриваются артериальная гипертензия и ишемическая болезнь сердца как состояния, имеющие множество точек соприкосновения их патогенеза. В качестве эффективной терапии этих состояний, способствующей также и профилактике развития осложнений, обсуждаются антагонисты рецепторов типа 1 ангиотензина II. Приводятся современные данные об этих средствах, обсуждаются показания к назначению.

The paper considers arterial hypertension and coronary heart disease as pathologies which share multiple pathogenetic mechanisms. The role of angiotensin II receptor antagonists (ARA) in the effective treatment of these diseases and in prevention of their complications is discussed. The modern views on ARA and their indications are presented.

атеросклерозгемостазтромбоцитылозартанatherosclerosishaemostasisplateletslosartanReferencesZhao H, Li M, Wang L, et al. Angiotensin II induces TSLP via an AT1 receptor, promoting Th17 differentiation. Cell Physiol Biochem 2012; 30(6): 1383-97.Zhao H, Li M, Wang L, et al. Angiotensin II induces TSLP via an AT1 receptor, promoting Th17 differentiation. Cell Physiol Biochem 2012; 30(6): 1383-97.Fang J, Ma L, Zhang S, et al. Association of myeloperoxidase gene variation with carotid atherosclerosis in patients with arterial hypertension. Mol Med Report 2012; Oct,23: 267.Fang J, Ma L, Zhang S, et al. Association of myeloperoxidase gene variation with carotid atherosclerosis in patients with arterial hypertension. Mol Med Report 2012; Oct,23: 267.Kishi T, Hirooka Y, Konno S, et al. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 2012; 30(8): 1646-55.Kishi T, Hirooka Y, Konno S, et al. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 2012; 30(8): 1646-55.Miyata M, Ikeda Y, Nakamura S, et al. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome. Circ J 2012; 76(4): 843-51.Miyata M, Ikeda Y, Nakamura S, et al. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome. Circ J 2012; 76(4): 843-51.Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: a target and contributor to dyslipidemias, altered glucose homeostasis and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302(6): 1219-30.Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: a target and contributor to dyslipidemias, altered glucose homeostasis and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302(6): 1219-30.Baehr IN, Tretter P, Krueger J, et al. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-gamma in patients with the metabolic syndrome. Hypertension 2011; 58: 725-32.Baehr IN, Tretter P, Krueger J, et al. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-gamma in patients with the metabolic syndrome. Hypertension 2011; 58: 725-32.Simonenko VB, Medvedev IN, Tolmachev VV. Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan. Klin Med 2011; 89: 35-8.Simonenko VB, Medvedev IN, Tolmachev VV. Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan. Klin Med 2011; 89: 35-8.Fogari R, Zoppi A, Mugellini A, et al. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertens Res 2011; 34: 1321-6.Fogari R, Zoppi A, Mugellini A, et al. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertens Res 2011; 34: 1321-6.Murad JP, Espinosa EV, Ting HJ, et al. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 2012; 17(3): 308-14.Murad JP, Espinosa EV, Ting HJ, et al. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 2012; 17(3): 308-14.Rossi GP. Losartan metbolite EXP3179. Hypertension 2009; 54: 710-2.Rossi GP. Losartan metbolite EXP3179. Hypertension 2009; 54: 710-2.Ono K, Ueda H, Yoshizawa Y, Akazawa D, et al. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan via glycoprotein VI. J Med Chem 2010; 53(5): 2087-93.Ono K, Ueda H, Yoshizawa Y, Akazawa D, et al. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan via glycoprotein VI. J Med Chem 2010; 53(5): 2087-93.Lee B-S, Choi JY, Kim JY, et al. Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein E-- mice. Korean Circ J 2012; 42(8): 543-50.Lee B-S, Choi JY, Kim JY, et al. Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein E-- mice. Korean Circ J 2012; 42(8): 543-50.Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.Mourad AA, Heeba GH, Taye A, et al. Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. Fundam Clin Pharmacol 2012; May,21.Mourad AA, Heeba GH, Taye A, et al. Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. Fundam Clin Pharmacol 2012; May,21.Akhavan MM, Karimi M, Ghodrati M, et al. AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells. Pak J Biol Sci 2011; 14(17): 821-30.Akhavan MM, Karimi M, Ghodrati M, et al. AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells. Pak J Biol Sci 2011; 14(17): 821-30.Choi CH, Park YA, Choi JJ, et al. Angiotensin II type 1 receptor and miR-155 endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cnacer cells. Gynecol Oncol 2012; 126(1): 124-31.Choi CH, Park YA, Choi JJ, et al. Angiotensin II type 1 receptor and miR-155 endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cnacer cells. Gynecol Oncol 2012; 126(1): 124-31.Li M, Liu J, Han C, et al. Angiotensin II induces the expression of c-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Cell Physiol Biochem 2011; 27(1): 63-70.Li M, Liu J, Han C, et al. Angiotensin II induces the expression of c-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Cell Physiol Biochem 2011; 27(1): 63-70.Thatcher SE, Zhang X, Howatt DA, et al. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor -/- mice. Arterioscler Thromb Vasc Biol 2011; 31(4): 758-65.Thatcher SE, Zhang X, Howatt DA, et al. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor -/- mice. Arterioscler Thromb Vasc Biol 2011; 31(4): 758-65.Sardo MA, Mandraffino G, Riggio S, et al. Effects of the angiotensin II receptort blocker losartan on the monocyte expression of biglycan in hypertensive patients. Clin Exp Pharmacol Physiol 2010; 37(9): 933-8.Sardo MA, Mandraffino G, Riggio S, et al. Effects of the angiotensin II receptort blocker losartan on the monocyte expression of biglycan in hypertensive patients. Clin Exp Pharmacol Physiol 2010; 37(9): 933-8.

The authors declare that there are no conflicts of interest present.